Mehmet Asim Bilen, MD

One star
One star
One star
One star
One half star

Rating: 4.9 out of 5 (409 ratings)

Role

Medical Oncology
Specialty

Adrenal Cancer Bladder Cancer Kidney (Renal) Cancer Penile Cancer Prostate Cancer Testicular Cancer
Research Program

Discovery and Developmental Therapeutics
Practicing Since

2016

Call 404-778-1900

Background

A board certified medical oncologist, Dr. Bilen is actively involved in clinical research and patient care in the area of genitourinary cancers. He serves as director of the Genitourinary Medical Oncology Program at Winship Cancer Institute of Emory University. He works closely with the Fellowship Program of the Department of Hematology and Medical Oncology by educating fellows on genitourinary oncology. He also serves on the Winship Clinical and Translational Review Committee.

See Dr. Bilen's publications here.

Titles & Roles

Associate Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine
Director, Genitourinary Medical Oncology Program

Winship Cancer Institute of Emory University

Education & Training

Education

Fellowship, Hematology & Oncology, 2016
UT MD Anderson Cancer Center
Residency, Internal Medicine, 2013
Baylor College of Medicine
Internship, Internal Medicine, 2011
Baylor College of Medicine
Medical Education, MD, 2008
Hacettepe University Faculty of Medicine

Board Certifications

Medical Oncology
American Board of Internal Medicine, 2016
Internal Medicine
American Board of Internal Medicine, 2013

Professional Memberships

American Association for Cancer Research
American Society of Clinical Oncology

Research

View Current Clinical Trials


Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial Phase II Conditions Advanced Renal Cell Carcinoma Location Winship Cancer Institute
Study of AZD0754 in Participants With Metastatic Prostate Cancer Phase I/II Conditions Metastatic Prostate Cancer Location Emory University Hospital Midtown, Winship Cancer Institute
A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS) Phase I Conditions Solid Tumor, Adult Location Winship Cancer Institute
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors Phase I Conditions Clear Cell Renal Cell Carcinoma, Solid Tumors Location Winship Cancer Institute
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer Phase II Conditions Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Sporadic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8 Location Emory University Hospital Midtown, Emory Saint Joseph's Hospital, Winship Cancer Institute
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer Phase I Conditions Prostate Cancer Location Winship Cancer Institute
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 Phase I Conditions Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms Location Winship Cancer Institute
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors Phase I Conditions Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma, Renal Cell Carcinoma, Clear Cell, Castration-resistant Prostate Cancer, Ovarian Cancer, Epithelial, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer Location Winship Cancer Institute
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors Phase I Conditions Metastatic Solid Tumor, Advanced Solid Tumor Location Winship Cancer Institute
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma Phase I Conditions Clear Cell Renal Cell Carcinoma Location Emory University Hospital Midtown, Winship Cancer Institute
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer Phase I Conditions Metastatic Prostate Cancer Location Winship Cancer Institute
Cabozantinib in Combination with Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer Phase I Conditions Infiltrating Bladder Urothelial Carcinoma with Squamous Differentiation, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma Location Emory University Hospital Midtown, Emory Saint Joseph's Hospital, Winship Cancer Institute
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Phase II Conditions Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Neuroendocrine Carcinoma, Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Collecting Duct Carcinoma, Invasive Bladder Giant Cell Urothelial Carcinoma, Invasive Bladder Lymphoepithelioma-Like Carcinoma, Invasive Bladder Nested Urothelial Carcinoma, Invasive Bladder Plasmacytoid Urothelial Carcinoma, Invasive Bladder Sarcomatoid Urothelial Carcinoma, Invasive Bladder Urothelial Carcinoma, Kidney Medullary Carcinoma, Large Cell Neuroendocrine Carcinoma, Malignant Testicular Leydig Cell Tumor, Malignant Testicular Sertoli Cell Tumor, Metastatic Bladder Carcinoma, Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma, Metastatic Bladder Giant Cell Urothelial Carcinoma, Metastatic Bladder Large Cell Neuroendocrine Carcinoma, Metastatic Bladder Lipid-Rich Urothelial Carcinoma, Metastatic Bladder Micropapillary Urothelial Carcinoma, Metastatic Bladder Plasmacytoid Urothelial Carcinoma, Metastatic Bladder Sarcomatoid Urothelial Carcinoma, Metastatic Bladder Small Cell Neuroendocrine Carcinoma, Metastatic Bladder Squamous Cell Carcinoma, Metastatic Chromophobe Renal Cell Carcinoma, Metastatic Kidney Medullary Carcinoma, Metastatic Malignant Genitourinary System Neoplasm, Metastatic Papillary Renal Cell Carcinoma, Metastatic Penile Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Metastatic Urethral Carcinoma, Papillary Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Urachal Adenocarcinoma, Urethral Clear Cell Adenocarcinoma Location Winship Cancer Institute

Publications

Dr. Bilen has published a number of peer-reviewed original papers and reviews in leading journals including Cancer Research, Molecular Cancer Research, FASEB J, Journal of Pathology, Cancer and Clinical and Experimental Metastasis and has authored or co-authored several abstracts for presentations at professional meetings.

Title/Journal	Authors	Publication Date
Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer. Advances in therapy	MA Bilen, B Lowentritt, I Khilfeh, C Rossi, S Du, F Kinkead, L Diaz, D Pilon, L Ellis, ND Shore	07/01/2025
Overall survival in patients with metastatic castration-sensitive prostate cancer treated with apalutamide versus abiraterone acetate: a head-to-head analysis of real-world patients in the USA. Journal of comparative effectiveness research	B Lowentritt, MA Bilen, I Khilfeh, C Rossi, S Du, F Kinkead, L Diaz, D Pilon, L Ellis, ND Shore	07/01/2025
Somatic yolk sac tumors in the urinary tract: A form of rare divergent differentiation. Human pathology	N Tedrow, K Ogan, S Joshi, MA Bilen, J Brown, B Carthon, F Saeed, J Gandhi, E Genega, L Harik	06/25/2025
Comparison of Real-World Outcomes between Patients with BRCA1/2-Positive and Homologous Recombination Repair-Negative Metastatic Castration-Sensitive Prostate Cancer. Advances in therapy	MA Bilen, S Burbage, C Rossi, I Khilfeh, L Diaz, Y Wang, D Pilon, G Brown, N Shore, B Lowentritt, DW Lin	06/17/2025
REFINE: a database of linked clinical data and genomic biomarkers in renal cell carcinoma patients receiving immunotherapy-based treatment regimens. The oncologist	J Zhong, A Jang, B Abuqayas, A Basu, DJ Benjamin, V Bhatlapenumarthi, MA Bilen, D Buch, M Chang, E Chin, S Darabi, N Dhanikonda, P Ghatalia, CM Grigg, AL Grier, T Jindal, J Jung, D Kilari, HLS Kumar, S Lee, B Neelands, C Pandya, J Pawalek, J Staggers, A Yildirim, Y Zakharia, KK Zarrabi, M Zimmerman, G Sledge, D Spetzler, A Elliott, RR McKay, PC Barata	06/04/2025
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration. Prostate cancer and prostatic diseases	ZB Zengin, NC Henderson, JJ Park, A Ali, C Nguyen, C Hwang, PC Barata, MA Bilen, L Graham, G Mo, D Kilari, A Tripathi, M Labriola, S Rothstein, R Garje, VS Koshkin, VG Patel, MT Schweizer, AJ Armstrong, RR McKay, A Alva, T Dorff	06/01/2025
Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer. Prostate cancer and prostatic diseases	A Broderick, E Pan, J Li, A Chu, C Hwang, PC Barata, FC Cackowski, M Labriola, A Ghose, MA Bilen, D Kilari, B Thapa, M Piero, L Graham, A Tripathi, R Garje, VS Koshkin, E Hernandez, TB Dorff, MT Schweizer, AS Alva, RR McKay, AJ Armstrong	06/01/2025
Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma. Cancer discovery	MB Hugaboom, LV Wirth, K Street, N Ruthen, OA Jegede, NR Schindler, V Shah, JP Zaemes, N El Ahmar, S Matar, V Savla, TK Choueiri, T Denize, DJ West, DF McDermott, ER Plimack, JA Sosman, NB Haas, MN Stein, R Alter, MA Bilen, ME Hurwitz, H Hammers, S Signoretti, MB Atkins, CJ Wu, DA Braun	05/02/2025
Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10). Urologic oncology	AO Siefker-Radtke, RA Huddart, MA Bilen, A Balar, D Castellano, SS Sridhar, U De Giorgi, K Penkov, A Vasiliev, A Peer, R Järvinen, H Harputluoğlu, VS Koshkin, S Poushnejad, T Wang, A Qureshi, MA Tagliaferri, J Zalevsky, Y Loriot	05/01/2025
Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma: The PemCab Trial. European urology oncology	RK Jain, U Swami, MA Bilen, G Gebrael, KM Boucher, E Braun, JT Brown, J Chahoud, S Gupta, N Agarwal, G Sonpavde, BL Maughan	04/29/2025
Trop-2 and Ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes. American journal of clinical pathology	KB Case, DJ Martini, MN Dababneh, S Bidot, B Nazha, J Brown, S Joshi, V Narayan, V Parihar, F Saeed, MA Bilen, LR Harik	04/19/2025
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data. European urology oncology	T Jindal, C Jiang, O Alhalabi, A Nizam, C Nguyen, R Talukder, D Bakaloudi, M Davidsohn, D Freeman, M Glover, AR Khaki, S Evans, E Lemke, R Bose, W Sim, C Pywell, A Basu, D Kilari, PC Barata, MA Bilen, Y Zakharia, MI Milowsky, SA Shah, J Bellmunt, P Grivas, H Emamekhoo, NB Davis, S Gupta, C Hoimes, MT Campbell, A Alva, VS Koshkin	04/01/2025
A multi-perspective study assessing Black and African American participation barriers in prostate cancer clinical trials. Future oncology (London, England)	P Leger, S Frencher, JT Nauseef, B Jones, MA Bilen, A Brown, A Ullah, S McDevitt, CK Tsao	04/01/2025
Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial. Nature cancer	MA Bilen, BT Vo, Y Liu, R Greenwald, AH Davarpanah, D McGuire, R Shiradkar, L Li, A Midya, B Nazha, JT Brown, S Williams, W Session, G Russler, S Caulfield, SS Joshi, VM Narayan, CP Filson, K Ogan, O Kucuk, BC Carthon, L Del Balzo, A Cohen, A Boyanton, N Prokhnevska, MA Cardenas, E Sobierajska, CS Jansen, DH Patil, E Nicaise, AO Osunkoya, HT Kissick, VA Master	03/01/2025
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes. Prostate cancer and prostatic diseases	NA Zorko, A Makovec, A Elliott, S Kellen, JR Lozada, AT Arafa, M Felices, M Shackelford, P Barata, Y Zakharia, V Narayan, MN Stein, KK Zarrabi, A Patniak, MA Bilen, M Radovich, G Sledge, WS El-Deiry, EI Heath, DSB Hoon, C Nabhan, JS Miller, JH Hwang, ES Antonarakis	03/01/2025
Diuresis During ¹⁸F-Flotufolastat (rhPSMA-7.3) PET/CT Improves Recurrence Detection After Prostatectomy: A Prospective Phase II Trial. Journal of nuclear medicine : official publication, Society of Nuclear Medicine	IO Lawal, A Mushtaq, AB Jani, M Rupji, VR Dhere, SA Patel, MA Bilen, PR Patel, NT Sebastian, JM Switchenko, DM Schuster, C Marcus	02/03/2025
Characteristics, Treatment, and Outcomes of Primary Urethral Cancer: A Multicenter Review Over Two Decades. Clinical genitourinary cancer	BD Hopkins, DC Qian, KM Xu, A McCook-Veal, J Switchenko, LM Hartsell, CB Cimmino, SS Joshi, V Narayan, VA Master, B Nazha, BC Carthon, MA Bilen, O Kucuk, JW Shelton, PR Patel, AB Jani, JS Remick, TY Eng	02/01/2025
Real-World Outcomes in Patients with Advanced Penile Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Single Institution Experience. Journal of immunotherapy and precision oncology	TZ Zhuang, S Goyal, KB Case, TA Olsen, S Vemuru, A Yildirim, RV Goswamy, JT Brown, BC Carthon, O Kucuk, MA Bilen, VA Master, B Nazha	02/01/2025
Treatment patterns for patients with BRCA1/2-positive metastatic castration-resistant prostate cancer. The oncologist	MA Bilen, I Khilfeh, C Rossi, L Morrison, L Diaz, A Hilts, P Lefebvre, D Pilon, DJ George	01/17/2025
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. The New England journal of medicine	AB Apolo, KV Ballman, G Sonpavde, S Berg, WY Kim, R Parikh, MY Teo, RF Sweis, DM Geynisman, P Grivas, G Chatta, ZR Reichert, JW Kim, MA Bilen, B McGregor, P Singh, A Tripathi, S Cole, N Simon, S Niglio, L Ley, L Cordes, S Srinivas, J Huang, M Odegaard, C Watt, D Petrylak, J Hoffman-Censits, Y Wen, O Hahn, C Mitchell, A Tan, H Streicher, E Sharon, H Moon, M Woods, S Halabi, G Perez Burbano, MJ Morris, JE Rosenberg	01/02/2025
The role of immunotherapy in targeting tumor microenvironment in genitourinary cancers. Frontiers in immunology	E Kalemoglu, Y Jani, K Canaslan, MA Bilen	01/01/2025
Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors. Therapeutic advances in medical oncology	A Yildirim, M Wei, Y Liu, B Nazha, JT Brown, BC Carthon, Y Choi, L Suh, RV Goswamy, GR McClintock, C Hartman, S Caulfield, J Ciuro, JM Goldman, WB Harris, O Kucuk, VA Master, MA Bilen	01/01/2025
Recent progress in non-clear cell renal cell carcinoma: biology and therapeutic strategies. Therapeutic advances in medical oncology	A Yildirim, MW Moses, M Gerke, Y Jani, JC Thompson, U Akova, MA Bilen	01/01/2025
Understanding and overcoming resistance to immunotherapy in genitourinary cancers. Cancer biology & therapy	ST Evans, Y Jani, CS Jansen, A Yildirim, E Kalemoglu, MA Bilen	12/31/2024
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. Nature communications	MN Stein, EE Dumbrava, BA Teply, US Gergis, ME Guiterrez, R Reshef, SK Subudhi, CF Jacquemont, JH Senesac, JH Bayle, CD Scripture, MS Chatwal, MA Bilen, WM Stadler, CR Becerra	12/30/2024
Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers. Communications medicine	RM Barnett, A Jang, S Lanka, P Fu, LA Bucheit, H Babiker, A Bryce, HM Meyer, Y Choi, C Moore, R Garje, X Gao, DW Kim, RY Chang, P Gulhati, R Ramaker, R Bansal, T Zhang, A Oliver Sartor, AJ Armstrong, MA Bilen, P Barata	12/02/2024
Differentiation fate of a stem-like CD4 T cell controls immunity to cancer. Nature	MA Cardenas, N Prokhnevska, E Sobierajska, P Gregorova, CB Medina, RM Valanparambil, R Greenwald, L DelBalzo, MA Bilen, SS Joshi, VM Narayan, VA Master, MG Sanda, HT Kissick	12/01/2024
PD-L1 and nectin-4 expression and genomic characterization of bladder cancer with divergent differentiation. Cancer	DJ Martini, KB Case, D Gratz, K Pellegrini, E Beagle, T Schneider, M Dababneh, B Nazha, JT Brown, SS Joshi, VM Narayan, K Ogan, VA Master, BC Carthon, O Kucuk, LR Harik, MA Bilen	11/01/2024
Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146. European urology	CH Lee, A Yogesh Shah, A Rao, MH Taylor, C Di Simone, JJ Hsieh, A Pinto, R Gironés Sarrió, A Lee Cohn, M Asim Bilen, S Gunnestad Ribe, Ø Krohn Tennøe, D Richards, RF Sweis, J Courtright, D Heinrich, R Perini, P Kubiak, D Bock, CE Okpara, RJ Motzer	11/01/2024
Adrenocortical Carcinomas: Molecular Pathogenesis, Treatment Options, and Emerging Immunotherapy and Targeted Therapy Approaches. The oncologist	D Chukkalore, K MacDougall, V Master, MA Bilen, B Nazha	09/06/2024
Neoadjuvant cabozantinib restores CD8+ T cells in patients with locally advanced non-metastatic clear cell renal cell carcinoma: a phase 2 trial. Research square	MA Bilen, BT Vo, Y Liu, R Greenwald, AH Davarpanah, D McGuire, R Shiradkar, L Li, B Nazha, JT Brown, S Williams, W Session, G Russler, S Caulfield, SS Joshi, VM Narayan, CP Filson, K Ogan, O Kucuk, BC Carthon, L Del Balzo, A Cohen, A Boyanton, N Prokhnevska, MA Cardenas, E Sobierajska, CS Jansen, DH Patil, E Nicaise, AO Osunkoya, H Kissick, VA Master	08/08/2024
DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes. JCO precision oncology	LS Graham, NC Henderson, O Kellezi, C Hwang, PC Barata, MA Bilen, D Kilari, M Pierro, B Thapa, A Tripathi, G Mo, M Labriola, JJ Park, S Rothstein, R Garje, VS Koshkin, VG Patel, T Dorff, AJ Armstrong, RR McKay, A Alva, MT Schweizer	08/01/2024
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study. The Lancet. Oncology	ME Allaf, SE Kim, V Master, DF McDermott, LC Harshman, SM Cole, CG Drake, S Signoretti, M Akgul, N Baniak, E Li-Ning, MB Palmer, H Emamekhoo, N Adra, H Kaimakliotis, Y Ged, PM Pierorazio, EJ Abel, MA Bilen, K Ogan, HH Moon, KA Ramaswamy, EA Singer, TM Mayer, J Lohrey, V Margulis, J Gills, SE Delacroix, MJ Waples, AC James, P Wang, T Choueiri, MD Michaelson, A Kapoor, DY Heng, B Shuch, BC Leibovich, PN Lara, J Manola, D Maskens, D Battle, R Uzzo, G Bratslavsky, NB Haas, MA Carducci	08/01/2024
Circulating Tumor DNA in Genitourinary Cancers: Detection, Prognostics, and Therapeutic Implications. Cancers	MB Gerke, CS Jansen, MA Bilen	06/20/2024
The impact of cancer metastases on COVID-19 outcomes: A COVID-19 and Cancer Consortium registry-based retrospective cohort study. Cancer	CA Castellano, T Sun, D Ravindranathan, C Hwang, N Balanchivadze, SRK Singh, EA Griffiths, I Puzanov, E Ruiz-Garcia, D Vilar-Compte, AI Cárdenas-Delgado, RR McKay, TK Nonato, A Ajmera, PP Yu, R Nadkarni, TE O'Connor, S Berg, K Ma, D Farmakiotis, K Vieira, P Arvanitis, RM Saliby, C Labaki, T El Zarif, TM Wise-Draper, O Zamulko, N Li, BE Bodin, MK Accordino, M Ingham, M Joshi, HV Polimera, LA Fecher, CR Friese, JJ Yoon, BH Mavromatis, JT Brown, K Russell, R Nanchal, H Singh, L Tachiki, FA Moria, G Nagaraj, K Cortez, SH Abbasi, EM Wulff-Burchfield, M Puc, LB Weissmann, PS Bhatt, MG Mariano, S Mishra, S Halabi, A Beeghly, JL Warner, B French, MA Bilen	06/15/2024
Linear Muscle Segmentation for Metastatic Renal Cell Carcinoma: Changes in Clinic-Friendly Estimation Predict Survival Following Cytoreductive Nephrectomy. Clinical genitourinary cancer	EH Nicaise, BN Schmeusser, A Ali, E Midenberg, AR Palacios, B Hartsoe, E Kearns, S Ambadi, DH Patil, SS Joshi, VM Narayan, SP Psutka, B Nazha, JT Brown, K Ogan, MA Bilen, VA Master	06/01/2024
Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma. The Journal of clinical investigation	S Gulati, PC Barata, A Elliott, MA Bilen, EF Burgess, TK Choueiri, S Darabi, NA Dawson, BA Gartrell, HJ Hammers, EI Heath, D Magee, A Rao, CJ Ryan, P Twardowski, S Wei, J Brugarolas, T Zhang, MR Zibelman, C Nabhan, RR McKay	05/30/2024
Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade. Cancer	EJ Miller, TL Rose, BL Maughan, MI Milowsky, MA Bilen, BC Carthon, X Gao, S Rapisuwon, Q Zhao, M Yu, N Agarwal, MD Galsky	05/01/2024
Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions. Nature genetics	MP Purdue, D Dutta, MJ Machiela, BR Gorman, T Winter, D Okuhara, S Cleland, A Ferreiro-Iglesias, P Scheet, A Liu, C Wu, SO Antwi, J Larkin, SC Zequi, M Sun, K Hikino, A Hajiran, KA Lawson, F Cárcano, O Blanchet, B Shuch, KG Nepple, G Margue, D Sundi, WR Diver, MAAK Folgueira, A van Bokhoven, F Neffa, KM Brown, JN Hofmann, J Rhee, M Yeager, NR Cole, BD Hicks, MR Manning, AA Hutchinson, N Rothman, WY Huang, WM Linehan, A Lori, M Ferragu, M Zidane-Marinnes, SV Serrano, WJ Magnabosco, A Vilas, R Decia, F Carusso, LS Graham, K Anderson, MA Bilen, C Arciero, I Pellegrin, S Ricard, G Scelo, RE Banks, NS Vasudev, N Soomro, GD Stewart, A Adeyoju, S Bromage, D Hrouda, N Gibbons, P Patel, M Sullivan, A Protheroe, FI Nugent, MJ Fournier, X Zhang, LJ Martin, M Komisarenko, T Eisen, SA Cunningham, DC Connolly, RG Uzzo, D Zaridze, A Mukeria, I Holcatova, A Hornakova, L Foretova, V Janout, D Mates, V Jinga, S Rascu, M Mijuskovic, S Savic, S Milosavljevic, V Gaborieau, B Abedi-Ardekani, J McKay, M Johansson, L Phouthavongsy, L Hayman, J Li, I Lungu, SM Bezerra, AG Souza, CTG Sares, RB Reis, FP Gallucci, MD Cordeiro, M Pomerantz, GM Lee, ML Freedman, A Jeong, SE Greenberg, A Sanchez, RH Thompson, V Sharma, DD Thiel, CT Ball, D Abreu, ET Lam, WC Nahas, VA Master, AV Patel, JC Bernhard, ND Freedman, P Bigot, RM Reis, LM Colli, A Finelli, BJ Manley, C Terao, TK Choueiri, DM Carraro, R Houlston, JE Eckel-Passow, PH Abbosh, A Ganna, P Brennan, J Gu, SJ Chanock	05/01/2024
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles. The Journal of clinical investigation	P Barata, S Gulati, A Elliott, HJ Hammers, E Burgess, BA Gartrell, S Darabi, MA Bilen, A Basu, DM Geynisman, NA Dawson, MR Zibelman, T Zhang, S Wei, CJ Ryan, EI Heath, KA Poorman, C Nabhan, RR McKay	04/23/2024
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research	T Dorff, LG Horvath, K Autio, A Bernard-Tessier, MB Rettig, JP Machiels, MA Bilen, MP Lolkema, N Adra, S Rottey, R Greil, N Matsubara, DSW Tan, A Wong, H Uemura, C Lemech, J Meran, Y Yu, M Minocha, M McComb, HL Penny, V Gupta, X Hu, G Jurida, H Kouros-Mehr, MM Janát-Amsbury, T Eggert, B Tran	04/15/2024
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). Journal for immunotherapy of cancer	MB Atkins, OA Jegede, NB Haas, DF Mcdermott, MA Bilen, M Stein, J Sosman, R Alter, ER Plimack, MC Ornstein, M Hurwitz, DJ Peace, D Einstein, PJ Catalano, H Hammers, MM Regan	04/11/2024
Established and emerging biomarkers of immunotherapy in renal cell carcinoma. Immunotherapy	Y Jani, CS Jansen, MB Gerke, MA Bilen	04/01/2024
Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations. JCO precision oncology	JJ Park, A Chu, J Li, A Ali, RR McKay, C Hwang, MK Labriola, A Jang, D Kilari, G Mo, D Ravindranathan, LS Graham, A Sokolova, A Tripathi, A Pilling, T Jindal, A Ravindra, FC Cackowski, PL Sweeney, B Thapa, TS Amery, EI Heath, R Garje, Y Zakharia, VS Koshkin, MA Bilen, MT Schweizer, PC Barata, TB Dorff, M Cieslik, AS Alva, AJ Armstrong	04/01/2024
Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis. Journal for immunotherapy of cancer	JS Patel, Y Woo, A Draper, CS Jansen, JW Carlisle, PF Innominato, FA Lévi, L Dhabaan, VA Master, MA Bilen, MK Khan, MC Lowe, H Kissick, ZS Buchwald, DC Qian	03/26/2024
Genetic Profiling of African American Patients With Prostatic Adenocarcinoma Metastatic to the Lymph Nodes: A Pilot Study. Archives of pathology & laboratory medicine	S Bidot, J Yin, P Zhou, L Zhang, KK Deeb, G Smith, CE Hill, J Xiu, MA Bilen, KB Case, M Tinsley, B Carthon, LR Harik	03/01/2024
A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab. Future oncology (London, England)	CJ Hoimes, TW Flaig, MI Milowsky, TW Friedlander, MA Bilen, S Gupta, S Srinivas, JR Merchan, RR McKay, DP Petrylak, C Sasse, BH Moreno, Y Yu, AS Carret, JE Rosenberg	03/01/2024
2018 Leibovich prognostic model for renal cell carcinoma: Performance in a large population with special consideration of Black race. Cancer	BN Schmeusser, DH Patil, EH Nicaise, M Armas-Phan, R Nabavizadeh, VM Narayan, SS Joshi, K Ogan, AO Osunkoya, MA Bilen, VA Master	02/01/2024
The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers. Biomarker insights	null Seema Mustafa, CS Jansen, Y Jani, S Evans, TZ Zhuang, J Brown, B Nazha, V Master, MA Bilen	01/01/2024
Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial. BMJ oncology	M Tucker, YW Chen, MH Voss, BA McGregor, MA Bilen, MO Grimm, P Nathan, C Kollmannsberger, Y Tomita, B Huang, R Amezquita, M Mariani, A di Pietro, B Rini	01/01/2024
Cytoreductive surgery, systemic treatment, genetic evaluation, and patient perspective in a young adult with metastatic renal cell carcinoma. CA: a cancer journal for clinicians	EH Nicaise, A Yildirim, S Sheth, E Richter, MA Daneshmand, SK Maithel, K Ogan, MA Bilen, VA Master	01/01/2024
Homologous Recombination Repair Testing Patterns and Outcomes in mCRPC by Alteration Status and Race. ClinicoEconomics and outcomes research : CEOR	MA Bilen, I Khilfeh, C Rossi, E Muser, L Morrison, A Hilts, L Diaz, P Lefebvre, D Pilon, DJ George	01/01/2024
Perioperative systemic treatments in renal cell carcinoma. Frontiers in oncology	R Goswamy, E Kalemoglu, V Master, MA Bilen	01/01/2024
Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers. Cancer	B Nazha, T Zhuang, S Wu, JT Brown, D Magee, BC Carthon, O Kucuk, C Nabhan, PC Barata, EI Heath, CJ Ryan, RR McKay, VA Master, MA Bilen	12/15/2023
Creatinine to Cystatin-C Ratio in Renal Cell Carcinoma: A Clinically Pragmatic Prognostic Factor and Sarcopenia Biomarker. The oncologist	BN Schmeusser, H Biermann, EH Nicaise, AA Ali, DH Patil, E Midenberg, T Helman, M Armas-Phan, R Nabavizadeh, SS Joshi, VM Narayan, MA Bilen, SP Psutka, K Ogan, VA Master	12/11/2023
Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors. The oncologist	GE Sanda, JM Shabto, S Goyal, Y Liu, DJ Martini, B Nazha, JT Brown, LB Yantorni, G Anne Russler, S Caulfield, SS Joshi, VM Narayan, H Kissick, K Ogan, VA Master, BC Carthon, O Kucuk, MA Bilen	12/11/2023
Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast. The oncologist	CS Lalonde, JM Switchenko, M Behera, MA Bilen, TK Owonikoko, JL Kaufman, AK Nooka, CM Lewis, E Hitron, H Collins, EC Judson, OB Alese, R Donald Harvey, JW Carlisle	12/11/2023
The Genomic Landscape of Urothelial Carcinoma with High and Low ERBB2 Expression. Cancers	A Hadadi, HB Krause, A Elliott, JT Brown, B Nazha, LR Harik, BC Carthon, B Miron, C Nabhan, PC Barata, M Saleh, Y Yang, RR McKay, MA Bilen	12/06/2023
Prostate Cancer Skeletal Metastasis: A Spontaneous Evolution from Osteolytic to Osteoblastic Morphology without Treatment. World journal of nuclear medicine	IO Lawal, MA Bilen, RK Halkar, AB Jani, DM Schuster	12/01/2023
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study. eLife	G Nagaraj, S Vinayak, AR Khaki, T Sun, NM Kuderer, DM Aboulafia, JD Acoba, J Awosika, Z Bakouny, NB Balmaceda, T Bao, B Bashir, S Berg, MA Bilen, P Bindal, S Blau, BE Bodin, HT Borno, C Castellano, H Choi, J Deeken, A Desai, N Edwin, LE Feldman, DB Flora, CR Friese, MD Galsky, CJ Gonzalez, P Grivas, S Gupta, M Haynam, H Heilman, DL Hershman, C Hwang, C Jani, SR Jhawar, M Joshi, V Kaklamani, EJ Klein, N Knox, VS Koshkin, AA Kulkarni, DH Kwon, C Labaki, PE Lammers, KI Lathrop, MA Lewis, X Li, GL Lopes, GH Lyman, DF Makower, AH Mansoor, MJ Markham, SH Mashru, RR McKay, I Messing, V Mico, R Nadkarni, S Namburi, RH Nguyen, TK Nonato, TL O'Connor, OA Panagiotou, K Park, JM Patel, KG Patel, J Peppercorn, H Polimera, M Puc, YJ Rao, P Razavi, SA Reid, JW Riess, DR Rivera, M Robson, SJ Rose, AD Russ, L Schapira, PK Shah, MK Shanahan, LC Shapiro, M Smits, DG Stover, M Streckfuss, L Tachiki, MA Thompson, SM Tolaney, LB Weissmann, G Wilson, MT Wotman, EM Wulff-Burchfield, S Mishra, B French, JL Warner, MB Lustberg, MK Accordino, DP Shah	10/17/2023
Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study). The oncologist	MA Bilen, SB Robinson, A Schroeder, J Peng, R Kim, FX Liu, A Bhanegaonkar	09/07/2023
Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer. JAMA network open	C Hwang, NC Henderson, SC Chu, B Holland, FC Cackowski, A Pilling, A Jang, S Rothstein, M Labriola, JJ Park, A Ghose, MA Bilen, S Mustafa, D Kilari, MJ Pierro, B Thapa, A Tripathi, R Garje, A Ravindra, VS Koshkin, E Hernandez, MT Schweizer, AJ Armstrong, RR McKay, TB Dorff, AS Alva, PC Barata	09/05/2023
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	PH O'Donnell, MI Milowsky, DP Petrylak, CJ Hoimes, TW Flaig, N Mar, HH Moon, TW Friedlander, RR McKay, MA Bilen, S Srinivas, EF Burgess, C Ramamurthy, S George, DM Geynisman, S Bracarda, D Borchiellini, L Geoffrois, JP Maroto Rey, C Ferrario, AS Carret, Y Yu, M Guseva, B Homet Moreno, JE Rosenberg	09/01/2023
Identifying the Needs of Health Care Providers in Advanced First-Line Renal Cell Carcinoma: A Mixed-Methods Research. Clinical genitourinary cancer	P Lazure, MT Campbell, M Augustyniak, EA Jaimes, MA Bilen, EA Lemke, EP Cohen, G Jacobs	08/01/2023
Low Skeletal Muscle as a Risk Factor for Worse Survival in Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus. Clinical genitourinary cancer	BN Schmeusser, E Midenberg, AR Palacios, AA Ali, DH Patil, M Higgins, R Nabavizadeh, B Croll, M Williams, J Sheehy, B Zheng, VM Narayan, SS Joshi, K Ogan, SP Psutka, MA Bilen, VA Master	08/01/2023
COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease. Translational oncology	MYY Moey, C Hennessy, B French, JL Warner, MD Tucker, DJ Hausrath, DP Shah, JM DeCara, Z Bakouny, C Labaki, TK Choueiri, S Dent, N Akhter, R Ismail-Khan, L Tachiki, D Slosky, TS Polonsky, JA Awosika, A Crago, T Wise-Draper, N Balanchivadze, C Hwang, LA Fecher, CG Gomez, B Hayes-Lattin, MJ Glover, SA Shah, D Gopalakrishnan, EA Griffiths, DH Kwon, VS Koshkin, S Mahmood, B Bashir, T Nonato, P Razavi, RR McKay, G Nagaraj, E Oligino, M Puc, P Tregubenko, EM Wulff-Burchfield, Z Xie, TR Halfdanarson, D Farmakiotis, EJ Klein, EV Robilotti, GJ Riely, JB Durand, SS Hayek, L Kondapalli, S Berg, TE O'Connor, MA Bilen, C Castellano, MK Accordino, B Sibel, LB Weissmann, C Jani, DB Flora, L Rudski, MS Dutra, B Nathaniel, E Ruíz-García, D Vilar-Compte, S Gupta, A Morgans, A Nohria	08/01/2023
Combined Programmed Death-Ligand 1 and MET Inhibition: Has Papillary Renal Cell Carcinoma MET Its Match? Journal of clinical oncology : official journal of the American Society of Clinical Oncology	JT Brown, B Nazha, MA Bilen	05/10/2023
Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas. The oncologist	O Alhalabi, J Thouvenin, S Négrier, YA Vano, L Campedel, E Hasanov, Z Bakouny, AW Hahn, MA Bilen, P Msaouel, TK Choueiri, SR Viswanathan, K Sircar, L Albiges, GG Malouf, NM Tannir	05/08/2023
Clinicopathologic analysis of patients undergoing repeat transurethral resection of bladder tumour following an initial diagnosis of urothelial carcinoma with lamina propria invasion and variant/divergent histology. Journal of clinical pathology	P Mullane, S Joshi, M Bilen, AO Osunkoya	04/01/2023
Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma. BMC cancer	DB Johnson, MB Atkins, C Hennessy, T Wise-Draper, H Heilman, J Awosika, Z Bakouny, C Labaki, RM Saliby, C Hwang, SRK Singh, N Balanchivadze, CR Friese, LA Fecher, JJ Yoon, B Hayes-Lattin, MA Bilen, CA Castellano, GH Lyman, L Tachiki, SA Shah, MJ Glover, DB Flora, E Wulff-Burchfield, A Kasi, SH Abbasi, D Farmakiotis, K Viera, EJ Klein, LB Weissman, C Jani, M Puc, CC Fahey, DY Reuben, S Mishra, A Beeghly-Fadiel, B French, JL Warner	03/23/2023
Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. The oncologist	TZ Zhuang, D Ravindranathan, Y Liu, DJ Martini, JT Brown, B Nazha, G Russler, LB Yantorni, S Caulfield, BC Carthon, O Kucuk, VA Master, MA Bilen	03/17/2023
Race-free renal function estimation equations and potential impact on Black patients: Implications for cancer clinical trial enrollment. Cancer	BN Schmeusser, AR Palacios, ER Midenberg, R Nabavizadeh, DH Patil, RD Harvey, J Bryksin, MJ Connor, K Ogan, MA Bilen, VA Master	03/15/2023
Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. medRxiv : the preprint server for health sciences	G Nagaraj, S Vinayak, AR Khaki, T Sun, NM Kuderer, DM Aboulafia, JD Acoba, J Awosika, Z Bakouny, NB Balmaceda, T Bao, B Bashir, S Berg, MA Bilen, P Bindal, S Blau, BE Bodin, HT Borno, C Castellano, H Choi, J Deeken, A Desai, N Edwin, LE Feldman, DB Flora, CR Friese, MD Galsky, CJ Gonzalez, P Grivas, S Gupta, M Haynam, H Heilman, DL Hershman, C Hwang, C Jani, SR Jhawar, M Joshi, V Kaklamani, EJ Klein, N Knox, VS Koshkin, AA Kulkarni, DH Kwon, C Labaki, PE Lammers, KI Lathrop, MA Lewis, X Li, G de Lima Lopes, GH Lyman, DF Makower, AH Mansoor, MJ Markham, SH Mashru, RR McKay, I Messing, V Mico, R Nadkarni, S Namburi, RH Nguyen, TK Nonato, TL O'Connor, OA Panagiotou, K Park, JM Patel, KG Patel, J Peppercorn, H Polimera, M Puc, YJ Rao, P Razavi, SA Reid, JW Riess, DR Rivera, M Robson, SJ Rose, AD Russ, L Schapira, PK Shah, MK Shanahan, LC Shapiro, M Smits, DG Stover, M Streckfuss, L Tachiki, MA Thompson, SM Tolaney, LB Weissmann, G Wilson, MT Wotman, EM Wulff-Burchfield, S Mishra, B French, JL Warner, MB Lustberg, MK Accordino, DP Shah	03/10/2023
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B). Journal for immunotherapy of cancer	MB Atkins, OA Jegede, NB Haas, DF McDermott, MA Bilen, M Stein, JA Sosman, R Alter, ER Plimack, MC Ornstein, M Hurwitz, DJ Peace, S Signoretti, T Denize, A Cimadamore, CJ Wu, D Braun, D Einstein, PJ Catalano, H Hammers	03/01/2023
Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma. Clinical genitourinary cancer	AM Shayeb, HD McManus, D Urman, C Jani, T Zhang, N Dizman, L Meza, A Sivakumar, CL Gan, P Barata, MA Bilen, X Gao, D Heng, S Pal, R Narra, D Kilari, MD Kaymakcalan, B McGregor, TK Choueiri, RR McKay	02/01/2023
Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study. JCO precision oncology	ES Yang, S Halabi, M Rothe, E Garrett-Mayer, PK Mangat, E Pisick, E Dib, EF Burgess, M Zakem, N Rohatgi, MA Bilen, R O'Lone, GN Grantham, RL Schilsky	02/01/2023
Neoadjuvant Nivolumab and Ipilimumab for Nonmetastatic Renal Cell Carcinoma with Tumor Thrombus. Journal of immunotherapy and precision oncology	VA Master, BN Schmeusser, AO Osunkoya, AR Palacios, E Midenberg, L Yantorni, K Ogan, MA Bilen	02/01/2023
CD8⁺ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity	N Prokhnevska, MA Cardenas, RM Valanparambil, E Sobierajska, BG Barwick, C Jansen, A Reyes Moon, P Gregorova, L delBalzo, R Greenwald, MA Bilen, M Alemozaffar, S Joshi, C Cimmino, C Larsen, V Master, M Sanda, H Kissick	01/10/2023
Challenges and opportunities in the management of non-urothelial bladder cancers. Cancer treatment and research communications	JT Brown, VM Narayan, SS Joshi, L Harik, AB Jani, MA Bilen	01/01/2023
Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma. Frontiers in oncology	CS Jansen, Y Choi, ST Evans, R Greenwald, JA Behnke, C Hartman, H Kissick, LR Harik, MA Bilen	01/01/2023
Editorial: Case reports in renal cell carcinoma. Frontiers in oncology	TZ Zhuang, SM Mustafa, KE Beckermann, MA Bilen	01/01/2023
Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19. JAMA oncology	Z Bakouny, C Labaki, P Grover, J Awosika, S Gulati, CY Hsu, SI Alimohamed, B Bashir, S Berg, MA Bilen, D Bowles, C Castellano, A Desai, A Elkrief, OE Eton, LA Fecher, D Flora, MD Galsky, ME Gatti-Mays, A Gesenhues, MJ Glover, D Gopalakrishnan, S Gupta, TR Halfdanarson, B Hayes-Lattin, M Hendawi, E Hsu, C Hwang, R Jandarov, C Jani, DB Johnson, M Joshi, H Khan, SA Khan, N Knox, VS Koshkin, AA Kulkarni, DH Kwon, S Matar, RR McKay, S Mishra, FA Moria, A Nizam, NL Nock, TK Nonato, J Panasci, L Pomerantz, AJ Portuguese, D Provenzano, M Puc, YJ Rao, TD Rhodes, GJ Riely, JJ Ripp, AV Rivera, E Ruiz-Garcia, AL Schmidt, AJ Schoenfeld, GK Schwartz, SA Shah, J Shaya, S Subbiah, LM Tachiki, MD Tucker, M Valdez-Reyes, LB Weissmann, MT Wotman, EM Wulff-Burchfield, Z Xie, YJ Yang, MA Thompson, DP Shah, JL Warner, Y Shyr, TK Choueiri, TM Wise-Draper	01/01/2023
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	CJ Hoimes, TW Flaig, MI Milowsky, TW Friedlander, MA Bilen, S Gupta, S Srinivas, JR Merchan, RR McKay, DP Petrylak, C Sasse, BH Moreno, Y Yu, AS Carret, JE Rosenberg	01/01/2023
Prognostic Value of Sarcopenia and Albumin in the Surgical Management of Localized Renal Cell Carcinoma. Urologic oncology	E Midenberg, MI Higgins, BN Schmeusser, DH Patil, J Zaldumbide, DJ Martini, S Steele, M Williams, R Nabavizadeh, SP Psutka, K Ogan, MA Bilen, VA Master	01/01/2023
Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas. The oncologist	J Thouvenin, O Alhalabi, M Carlo, L Carril-Ajuria, L Hirsch, N Martinez-Chanza, S Négrier, L Campedel, D Martini, D Borchiellini, J Chahoud, M Lodi, P Barthélémy, E Hasanov, AW Hahn, T Gil, SR Viswanathan, Z Bakouny, P Msaouel, M Asim Bilen, TK Choueiri, L Albiges, NM Tannir, GG Malouf	12/09/2022
Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [⁶⁸Ga]Ga DOTATATE PET-CT. Cancers	MA Bilen, A Akintayo, Y Liu, O Abiodun-Ojo, O Kucuk, BC Carthon, DM Schuster, EE Parent	12/08/2022
Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma. Clinical genitourinary cancer	R Talukder, D Makrakis, GI Lin, LN Diamantopoulos, S Dawsey, S Gupta, L Carril-Ajuria, D Castellano, I de Kouchkovsky, T Jindal, VS Koshkin, JJ Park, A Alva, MA Bilen, TF Stewart, RR McKay, N Tripathi, N Agarwal, N Vather-Wu, Y Zakharia, R Morales-Barrera, ME Devitt, A Cortellini, CAM Fulgenzi, DJ Pinato, A Nelson, CJ Hoimes, K Gupta, BA Gartrell, A Sankin, A Tripathi, R Zakopoulou, A Bamias, J Murgic, A Fröbe, A Rodriguez-Vida, A Drakaki, S Liu, E Lu, V Kumar, GD Lorenzo, M Joshi, P Isaacsson-Velho, LA Buznego, I Duran, M Moses, P Barata, G Sonpavde, JL Wright, EY Yu, RB Montgomery, AC Hsieh, P Grivas, AR Khaki	12/01/2022
Data regarding covariates significantly associated with sarcopenia and varying albumin statuses in patients with renal cell carcinoma. Data in brief	BN Schmeusser, DH Patil, E Midenberg, MI Higgins, J Zaldumbide, DJ Martini, S Steele, M Williams, R Nabavizadeh, SP Psutka, K Ogan, MA Bilen, VA Master	12/01/2022
Risk Stratification of Prostatic Adenocarcinoma Metastatic to the Lymph Nodes. Archives of pathology & laboratory medicine	S Bidot, A Monsrud, M Kline, A Speak, D Martini, MA Bilen, JM Switchenko, Y Zhang, AG Gerges, GN Farhat, EA Dent, VA Master, ML Tinsley, LR Harik	11/01/2022
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer. BJU international	D Makrakis, R Talukder, LN Diamantopoulos, L Carril-Ajuria, D Castellano, I De Kouchkovsky, VS Koshkin, JJ Park, A Alva, MA Bilen, TF Stewart, RR McKay, VS Santos, N Agarwal, J Jain, Y Zakharia, R Morales-Barrera, ME Devitt, M Grant, MP Lythgoe, DJ Pinato, A Nelson, CJ Hoimes, E Shreck, BA Gartrell, A Sankin, A Tripathi, R Zakopoulou, A Bamias, J Murgic, A Fröbe, A Rodriguez-Vida, A Drakaki, S Liu, V Kumar, G Di Lorenzo, M Joshi, P Isaacsson-Velho, LA Buznego, I Duran, M Moses, P Barata, G Sonpavde, EY Yu, JL Wright, P Grivas, AR Khaki	11/01/2022
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clinical genitourinary cancer	D Makrakis, R Talukder, GI Lin, LN Diamantopoulos, S Dawsey, S Gupta, L Carril-Ajuria, D Castellano, I de Kouchkovsky, VS Koshkin, JJ Park, A Alva, MA Bilen, TF Stewart, RR McKay, N Tripathi, N Agarwal, N Vather-Wu, Y Zakharia, R Morales-Barrera, ME Devitt, A Cortellini, CAM Fulgenzi, DJ Pinato, A Nelson, CJ Hoimes, K Gupta, BA Gartrell, A Sankin, A Tripathi, R Zakopoulou, A Bamias, J Murgic, A Fröbe, A Rodriguez-Vida, A Drakaki, S Liu, E Lu, V Kumar, GD Lorenzo, M Joshi, P Isaacsson-Velho, LA Buznego, I Duran, M Moses, A Jang, P Barata, G Sonpavde, EY Yu, RB Montgomery, P Grivas, AR Khaki	10/01/2022
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02. European urology	AO Siefker-Radtke, DC Cho, A Diab, M Sznol, MA Bilen, AV Balar, G Grignani, E Puente, L Tang, D Chien, U Hoch, A Choudhury, D Yu, SL Currie, MA Tagliaferri, J Zalevsky, ME Hurwitz, NM Tannir	10/01/2022
Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race. The oncologist	R Zimmerman, MA Bilen, EI Heath, L Nandagopal, U Swami, A Kessel, E Jaeger, S Wesolowski, EJ Hernanadez, J Chipman, A Mack, D Ravindranathan, BL Maughan, R Nussenzveig, M Yandell, M Kohli, MB Lilly, AO Sartor, N Agarwal, PC Barata	10/01/2022
Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study. Cancers	MJ Wagner, C Hennessy, A Beeghly, B French, DP Shah, S Croessmann, D Vilar-Compte, E Ruiz-Garcia, M Ingham, GK Schwartz, CA Painter, R Chugh, L Fecher, C Park, O Zamulko, JC Trent, V Subbiah, AR Khaki, L Tachiki, ES Nakasone, ET Loggers, C Labaki, RM Saliby, RR McKay, A Ajmera, EA Griffiths, I Puzanov, WD Tap, C Hwang, S Tejwani, SR Jhawar, B Hayes-Lattin, E Wulff-Burchfield, A Kasi, DY Reuben, G Nagaraj, M Joshi, H Polimera, AA Kulkarni, K Esfahani, DH Kwon, L Paoluzzi, MA Bilen, EB Durbin, P Grivas, JL Warner, EJ Davis	09/05/2022
An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. CA: a cancer journal for clinicians	E Hasanov, DN Yeboa, MD Tucker, TA Swanson, TH Beckham, B Rini, CI Ene, M Hasanov, S Derks, M Smits, S Dudani, DYC Heng, PK Brastianos, A Bex, S Hanalioglu, JS Weinberg, L Hirsch, MI Carlo, A Aizer, PD Brown, MA Bilen, EL Chang, J Jaboin, J Brugarolas, TK Choueiri, MB Atkins, BA McGregor, LM Halasz, TR Patel, SG Soltys, DF McDermott, JB Elder, MK Baskaya, JB Yu, R Timmerman, MM Kim, M Mut, J Markert, K Beal, NM Tannir, G Samandouras, FF Lang, R Giles, E Jonasch	09/01/2022
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). Journal of clinical oncology : official journal of the American Society of Clinical Oncology	MB Atkins, OA Jegede, NB Haas, DF McDermott, MA Bilen, M Stein, JA Sosman, R Alter, ER Plimack, M Ornstein, M Hurwitz, DJ Peace, S Signoretti, T Denize, A Cimadamore, CJ Wu, D Braun, D Einstein, PJ Catalano, H Hammers	09/01/2022
PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. Prostate cancer and prostatic diseases	VS Koshkin, VG Patel, A Ali, MA Bilen, D Ravindranathan, JJ Park, O Kellezi, M Cieslik, J Shaya, A Cabal, L Brown, M Labriola, LS Graham, C Pritchard, A Tripathi, S Nusrat, P Barata, A Jang, SR Chen, R Garje, L Acharya, C Hwang, A Pilling, W Oh, T Jun, D Natesan, C Nguyen, D Kilari, M Pierro, B Thapa, F Cackowski, A Mack, E Heath, CH Marshall, ST Tagawa, S Halabi, MT Schweizer, A Armstrong, T Dorff, A Alva, R McKay	09/01/2022
Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience. Journal of immunotherapy and precision oncology	DJ Martini, TA Olsen, S Goyal, Y Liu, ST Evans, EE Hitron, GA Russler, L Yantorni, S Caulfield, JT Brown, JM Goldman, B Nazha, BC Carthon, WB Harris, O Kucuk, VA Master, MA Bilen	08/01/2022
Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis. Critical reviews in oncology/hematology	IB Riaz, QUAR Sipra, SAA Naqvi, H He, R Siddiqi, M Islam, N Asghar, W Ikram, W Xu, H Liu, P Singh, TH Ho, MA Bilen, Y Zakharia, AH Bryce, MH Murad	07/01/2022
Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood. Journal for immunotherapy of cancer	JW Carlisle, CS Jansen, MA Cardenas, E Sobierajska, AM Reyes, R Greenwald, L Del Balzo, N Prokhnevska, O Kucuk, BC Carthon, PC Mullane, A Osunkoya, D Baumgarten, F Hosseinzadeh, S Wilkinson, R Lake, AG Sowalsky, Y Liu, VA Master, MA Bilen, H Kissick	07/01/2022
High throughput, label-free isolation of circulating tumor cell clusters in meshed microwells. Nature communications	M Boya, T Ozkaya-Ahmadov, BE Swain, CH Chu, N Asmare, O Civelekoglu, R Liu, D Lee, S Tobia, S Biliya, LD McDonald, B Nazha, O Kucuk, MG Sanda, BB Benigno, CS Moreno, MA Bilen, JF McDonald, AF Sarioglu	06/13/2022
Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials. Cancers	TZ Zhuang, K Case, TA Olsen, JT Brown, BC Carthon, O Kucuk, J Goldman, W Harris, MA Bilen, B Nazha	06/10/2022
Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma. The oncologist	B Nazha, TZ Zhuang, HI Dada, LM Drusbosky, JT Brown, D Ravindranathan, BC Carthon, O Kucuk, J Goldman, VA Master, MA Bilen	06/08/2022
Sarcopenia and systemic inflammation are associated with decreased survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Cancer	AI Khan, SP Psutka, DH Patil, G Hong, MA Williams, MA Bilen, A Sekhar, HT Kissick, VM Narayan, SS Joshi, K Ogan, VA Master	06/01/2022
Baseline basophil and basophil-to-lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancer. Urologic oncology	A Hadadi, KE Smith, L Wan, JR Brown, G Russler, L Yantorni, S Caulfield, J Lafollette, M Moore, O Kucuk, B Carthon, B Nazha, Y Liu, MA Bilen	06/01/2022
Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19. Blood cancer discovery	SM Rubinstein, D Bhutani, RC Lynch, CY Hsu, Y Shyr, S Advani, RA Mesa, S Mishra, DP Mundt, DP Shah, RA Sica, KE Stockerl-Goldstein, C Stratton, M Weiss, A Beeghly-Fadiel, M Accordino, SE Assouline, J Awosika, Z Bakouny, B Bashir, S Berg, MA Bilen, CA Castellano, JC Cogan, D Kc, CR Friese, S Gupta, D Hausrath, C Hwang, NA Johnson, M Joshi, A Kasi, EJ Klein, VS Koshkin, NM Kuderer, DH Kwon, C Labaki, T Latif, E Lau, X Li, GH Lyman, RR McKay, G Nagaraj, A Nizam, TK Nonato, AJ Olszewski, HV Polimera, AJ Portuguese, MM Puc, P Razavi, R Rosovski, A Schmidt, SA Shah, A Shastri, C Su, P Torka, TM Wise-Draper, L Zubiri, JL Warner, MA Thompson	05/05/2022
Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. Clinical genitourinary cancer	R Talukder, D Makrakis, LN Diamantopoulos, L Carril-Ajuria, D Castellano, I De Kouchkovsky, VS Koshkin, JJ Park, A Alva, MA Bilen, TF Stewart, RR McKay, VS Santos, N Agarwal, J Jain, Y Zakharia, R Morales-Barrera, ME Devitt, M Grant, MP Lythgoe, DJ Pinato, A Nelson, CJ Hoimes, E Shreck, BA Gartrell, A Sankin, A Tripathi, R Zakopoulou, A Bamias, J Murgic, A Fröbe, A Rodriguez-Vida, A Drakaki, S Liu, V Kumar, GD Lorenzo, M Joshi, PI Velho, LA Buznego, I Duran, M Moses, P Barata, G Sonpavde, EY Yu, JL Wright, P Grivas, AR Khaki	04/01/2022
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. Journal for immunotherapy of cancer	NM Tannir, DC Cho, A Diab, M Sznol, MA Bilen, AV Balar, G Grignani, E Puente, L Tang, D Chien, U Hoch, A Choudhury, D Yu, SL Currie, MA Tagliaferri, J Zalevsky, AO Siefker-Radtke, ME Hurwitz	04/01/2022
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer	VS Koshkin, N Henderson, M James, D Natesan, D Freeman, A Nizam, CT Su, AR Khaki, CK Osterman, MJ Glover, R Chiang, D Makrakis, R Talukder, E Lemke, TA Olsen, J Jain, A Jang, A Ali, T Jindal, J Chou, TW Friedlander, C Hoimes, A Basu, Y Zakharia, PC Barata, MA Bilen, H Emamekhoo, NB Davis, SA Shah, MI Milowsky, S Gupta, MT Campbell, P Grivas, GP Sonpavde, D Kilari, AS Alva	03/15/2022
Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer. The oncologist	MN Freeman, A Jang, J Zhu, F Sanati, L Nandagopal, D Ravindranathan, A Desai, A Phone, R Nussenzveig, E Jaeger, SA Caputo, VS Koshkin, U Swami, A Basu, MA Bilen, N Agarwal, O Sartor, EF Burgess, PC Barata	03/11/2022
Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. JAMA network open	J Fu, SA Reid, B French, C Hennessy, C Hwang, NT Gatson, N Duma, S Mishra, R Nguyen, JE Hawley, SRK Singh, DD Chism, NK Venepalli, JL Warner, TK Choueiri, AL Schmidt, LA Fecher, JE Girard, MA Bilen, D Ravindranathan, S Goyal, TM Wise-Draper, C Park, CA Painter, SM McGlown, G de Lima Lopes, OK Serrano, DP Shah	03/01/2022
Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research	MA Bilen, BI Rini, MH Voss, J Larkin, JBAG Haanen, L Albiges, LC Pagliaro, EG Voog, ET Lam, N Kislov, BA McGregor, AA Lalani, B Huang, A di Pietro, S Krulewicz, PB Robbins, TK Choueiri	02/15/2022
Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients. Clinical genitourinary cancer	DJ Martini, ST Evans, Y Liu, JM Shabto, OE Uner, TA Olsen, JT Brown, GA Russler, L Yantorni, S Caulfield, JM Goldman, B Nazha, WB Harris, VA Master, O Kucuk, BC Carthon, MA Bilen	02/01/2022
Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. JAMA network open	JE Hawley, T Sun, DD Chism, N Duma, JC Fu, NTN Gatson, S Mishra, RH Nguyen, SA Reid, OK Serrano, SRK Singh, NK Venepalli, Z Bakouny, B Bashir, MA Bilen, PF Caimi, TK Choueiri, SJ Dawsey, LA Fecher, DB Flora, CR Friese, MJ Glover, CJ Gonzalez, S Goyal, TR Halfdanarson, DL Hershman, H Khan, C Labaki, MA Lewis, RR McKay, I Messing, NA Pennell, M Puc, D Ravindranathan, TD Rhodes, AV Rivera, J Roller, GK Schwartz, SA Shah, JA Shaya, M Streckfuss, MA Thompson, EM Wulff-Burchfield, Z Xie, PP Yu, JL Warner, DP Shah, B French, C Hwang	01/04/2022
Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy. Frontiers in endocrinology	TA Olsen, TZ Zhuang, S Caulfield, DJ Martini, JT Brown, BC Carthon, O Kucuk, W Harris, MA Bilen, B Nazha	01/01/2022
Clinic friendly estimation of muscle composition: Preoperative linear segmentation shows overall survival correlated with muscle mass in patients with nonmetastatic renal cell carcinoma. Frontiers in oncology	BN Schmeusser, E Midenberg, AR Palacios, N Vettikattu, DH Patil, A Medline, M Higgins, M Armas-Phan, R Nabavizadeh, SS Joshi, VM Narayan, SP Psutka, K Ogan, MA Bilen, VA Master	01/01/2022
Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah's witness: A case report. Frontiers in oncology	TZ Zhuang, L Harik, S Force, A Hadadi, MA Bilen, JT Brown, BC Carthon, J Goldman, O Kucuk, VA Master, B Nazha	01/01/2022
Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA. Frontiers in oncology	U Swami, RM Zimmerman, RH Nussenzveig, EJ Hernandez, Y Jo, N Sayegh, S Wesolowski, LA Kiedrowski, PC Barata, GH Lemmon, MA Bilen, EI Heath, L Nandagopal, HM Babiker, SK Pal, M Lilly, BL Maughan, B Haaland, M Yandell, O Sartor, N Agarwal	01/01/2022
Correlates of financial toxicity in adult cancer patients and their informal caregivers. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer	G Sadigh, J Switchenko, KE Weaver, D Elchoufi, J Meisel, MA Bilen, D Lawson, D Cella, B El-Rayes, R Carlos	01/01/2022
Understanding Immunotherapy Terminology: An Analysis of Provider-Patient Conversations. Immunomedicine	S Blee, B Rosenberg, JM Switchenko, R Hianik, MC Thomson, M Dixon, MA Bilen, RD Pentz	12/01/2021
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. JAMA oncology	L Hirsch, N Martinez Chanza, S Farah, W Xie, R Flippot, DA Braun, N Rathi, J Thouvenin, KA Collier, E Seront, G de Velasco, H Dzimitrowicz, B Beuselinck, W Xu, IA Bowman, ET Lam, B Abuqayas, MA Bilen, A Varkaris, Y Zakharia, MR Harrison, A Mortazavi, P Barthélémy, N Agarwal, RR McKay, PK Brastianos, KM Krajewski, L Albigès, LC Harshman, TK Choueiri	12/01/2021
Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors. The oncologist	DJ Martini, JM Shabto, S Goyal, Y Liu, TA Olsen, ST Evans, BL Magod, D Ravindranathan, JT Brown, L Yantorni, GA Russler, S Caulfield, JM Goldman, B Nazha, SS Joshi, HT Kissick, KE Ogan, WB Harris, O Kucuk, BC Carthon, VA Master, MA Bilen	12/01/2021
Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. JAMA network open	AL Schmidt, MD Tucker, Z Bakouny, C Labaki, CY Hsu, Y Shyr, AJ Armstrong, TM Beer, RR Bijjula, MA Bilen, CF Connell, SJ Dawsey, B Faller, X Gao, BA Gartrell, D Gill, S Gulati, S Halabi, C Hwang, M Joshi, AR Khaki, H Menon, MJ Morris, M Puc, KB Russell, NJ Shah, N Sharifi, J Shaya, MT Schweizer, J Steinharter, EM Wulff-Burchfield, W Xu, J Zhu, S Mishra, P Grivas, BI Rini, JL Warner, T Zhang, TK Choueiri, S Gupta, RR McKay	11/01/2021
Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options. The oncologist	KER Smith, JT Brown, L Wan, Y Liu, G Russler, L Yantorni, S Caulfield, J Lafollette, M Moore, O Kucuk, B Carthon, B Nazha, MA Bilen	11/01/2021
Retrospective Study of Bleeding Risk with Concomitant Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor and Anticoagulation. The oncologist	A Sivakumar, SE Caulfield, C Zhang, S Goyal, MA Bilen, TJ Beardslee	11/01/2021
Negative enrichment of circulating tumor cells from unmanipulated whole blood with a 3D printed device. Scientific reports	CH Chu, R Liu, T Ozkaya-Ahmadov, BE Swain, M Boya, B El-Rayes, M Akce, MA Bilen, O Kucuk, AF Sarioglu	10/18/2021
Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going? Cancers	A Jang, DM Adler, GP Rauterkus, MA Bilen, PC Barata	10/10/2021
Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors. Clinical genitourinary cancer	GR Pond, A Agarwal, M Ornstein, J Garcia, R Gupta, P Grivas, A Drakaki, JL Lee, R Kanesvaran, GD Lorenzo, P Verolino, P Barata, MA Bilen, SA Hussain, C Curran, G Sonpavde	10/01/2021
Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. The oncologist	DJ Martini, S Goyal, Y Liu, ST Evans, TA Olsen, K Case, BL Magod, JT Brown, L Yantorni, GA Russler, S Caulfield, JM Goldman, B Nazha, WB Harris, HT Kissick, VA Master, O Kucuk, BC Carthon, MA Bilen	10/01/2021
Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU international	SM Esagian, AR Khaki, LN Diamantopoulos, L Carril-Ajuria, D Castellano, I De Kouchkovsky, JJ Park, A Alva, MA Bilen, TF Stewart, RR McKay, VS Santos, N Agarwal, J Jain, Y Zakharia, R Morales-Barrera, ME Devitt, A Nelson, CJ Hoimes, E Shreck, BA Gartrell, A Sankin, A Tripathi, R Zakopoulou, A Bamias, A Rodriguez-Vida, A Drakaki, S Liu, V Kumar, MP Lythgoe, DJ Pinato, J Murgic, A Fröbe, M Joshi, P Isaacsson Velho, N Hahn, L Alonso Buznego, I Duran, M Moses, P Barata, MD Galsky, G Sonpavde, EY Yu, P Msaouel, VS Koshkin, P Grivas	08/01/2021
Small-Cell Carcinoma of the Prostate: Report of Outcomes of Localized Disease Using the National Cancer Database. Clinical genitourinary cancer	KM Xu, Y Liu, TW Gillespie, AO Osunkoya, B Carthon, MA Bilen, CP Filson, K Ogan, PR Patel, JW Shelton, O Kucuk, S Joshi, AB Jani	08/01/2021
Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Journal for immunotherapy of cancer	JT Brown, Y Liu, JM Shabto, D Martini, D Ravindranathan, EE Hitron, GA Russler, S Caulfield, L Yantorni, SS Joshi, H Kissick, K Ogan, B Nazha, BC Carthon, O Kucuk, WB Harris, VA Master, MA Bilen	07/01/2021
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. The Lancet. Oncology	CH Lee, AY Shah, D Rasco, A Rao, MH Taylor, C Di Simone, JJ Hsieh, A Pinto, DR Shaffer, R Girones Sarrio, AL Cohn, NJ Vogelzang, MA Bilen, S Gunnestad Ribe, M Goksel, ØK Tennøe, D Richards, RF Sweis, J Courtright, D Heinrich, S Jain, J Wu, EV Schmidt, RF Perini, P Kubiak, CE Okpara, AD Smith, RJ Motzer	07/01/2021
Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma. Cancer	MI Higgins, DJ Martini, DH Patil, R Nabavizadeh, S Steele, M Williams, SS Joshi, VM Narayan, A Sekhar, SP Psutka, K Ogan, MA Bilen, VA Master	06/15/2021
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial. ESMO open	TK Choueiri, J Larkin, S Pal, RJ Motzer, BI Rini, B Venugopal, B Alekseev, H Miyake, G Gravis, MA Bilen, S Hariharan, A Chudnovsky, KA Ching, XJ Mu, M Mariani, PB Robbins, B Huang, A di Pietro, L Albiges	06/01/2021
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. European urology oncology	AR Khaki, A Li, LN Diamantopoulos, NJ Miller, L Carril-Ajuria, D Castellano, I De Kouchkovsky, V Koshkin, J Park, A Alva, MA Bilen, T Stewart, V Santos, N Agarwal, J Jain, Y Zakharia, R Morales-Barrera, M Devitt, A Nelson, CJ Hoimes, E Shreck, BA Gartrell, A Sankin, A Tripathi, R Zakopoulou, A Bamias, A Rodriguez-Vida, A Drakaki, S Liu, V Kumar, MP Lythgoe, DJ Pinato, J Murgic, A Fröbe, M Joshi, P Isaacsson Velho, N Hahn, L Alonso Buznego, I Duran, M Moses, P Barata, MD Galsky, G Sonpavde, EY Yu, V Shankaran, GH Lyman, P Grivas	06/01/2021
¹⁸F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial. Lancet (London, England)	AB Jani, E Schreibmann, S Goyal, R Halkar, B Hershatter, PJ Rossi, JW Shelton, PR Patel, KM Xu, M Goodman, VA Master, SS Joshi, O Kucuk, BC Carthon, MA Bilen, OA Abiodun-Ojo, AA Akintayo, VR Dhere, DM Schuster	05/22/2021
Circulating interleukin 6, androgen deprivation therapy, and fatigue in prostate cancer: Is inflammation the link? Cancer	B Nazha, MA Bilen	05/01/2021
Poorly Differentiated Neuroendocrine Tumor With 18F-Fluciclovine Uptake in a Patient With Metastatic Castrate-Resistant Prostate Cancer. Clinical nuclear medicine	OA Abiodun-Ojo, AA Akintayo, LR Harik, M Bilen, RK Halkar	05/01/2021
Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors. The oncologist	JT Brown, Y Liu, JM Shabto, DJ Martini, D Ravindranathan, EE Hitron, GA Russler, S Caulfield, LB Yantorni, SS Joshi, H Kissick, K Ogan, WB Harris, BC Carthon, O Kucuk, VA Master, MA Bilen	05/01/2021
Inflammatory Markers in Cancer Immunotherapy. Biology	D Ravindranathan, VA Master, MA Bilen	04/13/2021
Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos. Journal of visualized experiments : JoVE	S Steele, F Lin, TL Le, A Medline, M Higgins, A Sandberg, S Evans, G Hong, MA Williams, MA Bilen, S Psutka, K Ogan, VA Master	03/21/2021
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer	BA McGregor, MT Campbell, W Xie, S Farah, MA Bilen, AL Schmidt, GP Sonpavde, KL Kilbridge, AD Choudhury, A Mortazavi, AY Shah, AM Venkatesan, GJ Bubley, AO Siefker-Radtke, RR McKay, TK Choueiri	03/15/2021
Symptomatic methemoglobinemia in a patient with metastatic clear cell renal cell carcinoma treated with pembrolizumab and axitinib combination therapy: a case report. Journal of medical case reports	TA Olsen, DJ Martini, ST Evans, JM Goldman, MA Bilen	02/19/2021
Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody. American journal of clinical oncology	M Akce, Y Liu, K Zakka, DJ Martini, A Draper, OB Alese, WL Shaib, C Wu, JP Wedd, MT Sellers, MA Bilen, BF El-Rayes	02/01/2021
Successful Recruitment of Black Men to Prostate Cancer Clinical Trials-A Lesson in Achievement. JAMA network open	AW Hahn, MA Bilen, N Agarwal	01/04/2021
Landscape of Immunotherapy in Genitourinary Malignancies. Advances in experimental medicine and biology	D Ravindranathan, O Alhalabi, H Rafei, AY Shah, MA Bilen	01/01/2021
Exploratory study of ¹⁸F-fluciclovine pet/ct for response assessment to docetaxel in patients with metastatic castration-resistant prostate cancer. American journal of nuclear medicine and molecular imaging	AA Akintayo, MA Bilen, OA Abiodun-Ojo, O Kucuk, B Carthon, Z Chen, AB Jani, EE Parent, DM Schuster	01/01/2021
Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib. Cancer treatment and research communications	DJ Martini, MR Kline, Y Liu, JM Shabto, BC Carthon, GA Russler, L Yantorni, EE Hitron, S Caulfield, JM Goldman, WB Harris, O Kucuk, VA Master, MA Bilen	01/01/2021
Detection of Microsatellite Instability via Circulating Tumor DNA and Response to Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: A Case Series. Case reports in oncology	D Ravindranathan, GA Russler, L Yantorni, LM Drusbosky, MA Bilen	01/01/2021
Bladder preserving chemoradiotherapy compared to surgery for variants of urothelial carcinoma and other tumors types involving the bladder: An analysis of the National Cancer Database. Clinical and translational radiation oncology	JR Janopaul-Naylor, J Zhong, Y Liu, C Zhang, AO Osunkoya, SS Joshi, MA Bilen, B Carthon, O Kucuk, LM Hartsell, J Shelton, AB Jani	01/01/2021
Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors. Frontiers in oncology	DJ Martini, TA Olsen, S Goyal, Y Liu, ST Evans, B Magod, JT Brown, L Yantorni, GA Russler, S Caulfield, JM Goldman, B Nazha, HT Kissick, WB Harris, O Kucuk, BC Carthon, VA Master, MA Bilen	01/01/2021
Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma. Frontiers in oncology	DJ Martini, CS Jansen, LR Harik, ST Evans, TA Olsen, VA Master, HT Kissick, MA Bilen	01/01/2021
Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade. Frontiers in oncology	TA Olsen, DJ Martini, S Goyal, Y Liu, ST Evans, B Magod, JT Brown, L Yantorni, GA Russler, S Caulfield, JM Goldman, WB Harris, O Kucuk, BC Carthon, VA Master, B Nazha, MA Bilen	01/01/2021
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer. Future oncology (London, England)	RA Huddart, AO Siefker-Radtke, AV Balar, MA Bilen, T Powles, A Bamias, D Castellano, MF Khalil, MS Van Der Heijden, VS Koshkin, DW Pook, M Özgüroğlu, L Santiago, B Zhong, D Chien, W Lin, MA Tagliaferri, Y Loriot	01/01/2021
Initial Report of a Randomized Trial Comparing Conventional- vs Conventional plus Fluciclovine (¹⁸F) PET/CT Imaging-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer. International journal of radiation oncology, biology, physics	A Jani, E Schreibmann, S Goyal, H Raghuveer, B Hershatter, PJ Rossi, JW Shelton, PR Patel, KM Xu, M Goodman, V Master, SS Joshi, O Kucuk, B Carthon, MA Bilen, S Cooper, B Fielder, O Abiodun-Ojo, VR Dhere, DM Schuster	12/01/2020
Quantification of body composition in renal cell carcinoma patients: Comparing computed tomography and magnetic resonance imaging measurements. European journal of radiology	MI Higgins, DJ Martini, DH Patil, S Steele, S Evans, BP Petrinec, SP Psutka, A Sekhar, MA Bilen, VA Master	11/01/2020
Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. British journal of cancer	RD Harvey, BC Carthon, C Lewis, MS Hossain, C Zhang, Z Chen, WB Harris, OB Alese, W Shaib, MA Bilen, DH Lawson, C Wu, CE Steuer, BF El-Rayes, FR Khuri, S Lonial, EK Waller, SS Ramalingam, TK Owonikoko	10/01/2020
Considerations for cancer immunotherapy biomarker research during COVID-19. Endocrine-related cancer	JW Carlisle, CS Jansen, MA Bilen, H Kissick	09/01/2020
Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. European journal of cancer (Oxford, England : 1990)	BA McGregor, AA Lalani, W Xie, JA Steinharter, Z E Bakouny, DJ Martini, JH Fleischer, S Abou-Alaiwi, A Nassar, PV Nuzzo, MD Kaymakcalan, DA Braun, XX Wei, LC Harshman, MA Bilen, TK Choueiri	08/01/2020
Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. The oncologist	S Das, KK Ciombor, S Haraldsdottir, Y Pumpalova, IH Sahin, G Pineda, Y Shyr, EP Lin, CY Hsu, SK Chu, LW Goff, DB Cardin, MA Bilen, GA Fisher, C Wu, J Berlin	08/01/2020
Reply to Body fat indices and survival in immunotherapy-treated patients with cancer. Cancer	DJ Martini, Y Liu, VA Master, RD Harvey, MA Bilen	07/01/2020
Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. The Journal of urology	NJ Miller, AR Khaki, LN Diamantopoulos, MA Bilen, V Santos, N Agarwal, R Morales-Barrera, M Devitt, A Nelson, CJ Hoimes, E Shreck, H Assi, BA Gartrell, A Sankin, A Rodriguez-Vida, M Lythgoe, DJ Pinato, A Drakaki, M Joshi, P Isaacsson Velho, N Hahn, S Liu, L Alonso Buznego, I Duran, M Moses, J Jain, J Murgic, P Barata, A Tripathi, Y Zakharia, MD Galsky, G Sonpavde, EY Yu, GH Lyman, P Grivas	07/01/2020
Dynamic Evaluation of the Modified Glasgow Prognostic Scale in Patients With Resected, Localized Clear Cell Renal Cell Carcinoma. Urology	D Patil, TL Le, KB Bens, M Alemozaffar, A Lay, J Pattaras, CP Filson, K Ogan, MA Bilen, VA Master	07/01/2020
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet (London, England)	NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, S Shete, CY Hsu, A Desai, G de Lima Lopes, P Grivas, CA Painter, S Peters, MA Thompson, Z Bakouny, G Batist, T Bekaii-Saab, MA Bilen, N Bouganim, MB Larroya, D Castellano, SA Del Prete, DB Doroshow, PC Egan, A Elkrief, D Farmakiotis, D Flora, MD Galsky, MJ Glover, EA Griffiths, AP Gulati, S Gupta, N Hafez, TR Halfdanarson, JE Hawley, E Hsu, A Kasi, AR Khaki, CA Lemmon, C Lewis, B Logan, T Masters, RR McKay, RA Mesa, AK Morgans, MF Mulcahy, OA Panagiotou, P Peddi, NA Pennell, K Reynolds, LR Rosen, R Rosovsky, M Salazar, A Schmidt, SA Shah, JA Shaya, J Steinharter, KE Stockerl-Goldstein, S Subbiah, DC Vinh, FH Wehbe, LB Weissmann, JT Wu, E Wulff-Burchfield, Z Xie, A Yeh, PP Yu, AY Zhou, L Zubiri, S Mishra, GH Lyman, BI Rini, JL Warner	06/20/2020
A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research	TK Owonikoko, RD Harvey, B Carthon, Z Chen, C Lewis, H Collins, C Zhang, DH Lawson, OB Alese, MA Bilen, GL Sica, CE Steuer, WL Shaib, C Wu, WB Harris, M Akce, RR Kudchagkar, BF El-Rayes, S Lonial, SS Ramalingam, FR Khuri	06/01/2020
In Reply. The oncologist	MA Bilen, VA Master, RD Harvey	05/01/2020
Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors. Cancer medicine	JM Shabto, DJ Martini, Y Liu, D Ravindranathan, J Brown, EE Hitron, GA Russler, S Caulfield, H Kissick, M Alemozaffar, K Ogan, WB Harris, VA Master, O Kucuk, BC Carthon, MA Bilen	04/01/2020
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer	AR Khaki, A Li, LN Diamantopoulos, MA Bilen, V Santos, J Esther, R Morales-Barrera, M Devitt, A Nelson, CJ Hoimes, E Shreck, H Assi, BA Gartrell, A Sankin, A Rodriguez-Vida, M Lythgoe, DJ Pinato, A Drakaki, M Joshi, P Isaacsson Velho, N Hahn, S Liu, L Alonso Buznego, I Duran, M Moses, J Jain, J Murgic, P Baratam, P Barata, A Tripathi, Y Zakharia, MD Galsky, G Sonpavde, EY Yu, V Shankaran, GH Lyman, P Grivas	03/15/2020
Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. The oncologist	MA Bilen, DJ Martini, Y Liu, JM Shabto, JT Brown, M Williams, AI Khan, A Speak, C Lewis, H Collins, HT Kissick, BC Carthon, M Akce, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, BF El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey, VA Master	03/01/2020
Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. The oncologist	DJ Martini, Y Liu, JM Shabto, BC Carthon, EE Hitron, GA Russler, S Caulfield, HT Kissick, WB Harris, O Kucuk, VA Master, MA Bilen	03/01/2020
Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. Cancer	DJ Martini, MR Kline, Y Liu, JM Shabto, MA Williams, AI Khan, C Lewis, H Collins, M Akce, HT Kissick, BC Carthon, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, BF El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey, VA Master, MA Bilen	02/01/2020
Multidisciplinary Care of Adult Wilms' Tumor During Pregnancy: A Case Report and Review of the Literature. Clinical genitourinary cancer	JT Brown, LR Harik, MS Barbee, N Esiashvili, ML Badell, KC Goldsmith, VA Master, MA Bilen	02/01/2020
Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma. Journal for immunotherapy of cancer	S Abou Alaiwi, W Xie, AH Nassar, S Dudani, D Martini, Z Bakouny, JA Steinharter, PV Nuzzo, R Flippot, N Martinez-Chanza, X Wei, BA McGregor, MD Kaymakcalan, DYC Heng, MA Bilen, TK Choueiri, LC Harshman	02/01/2020
Ramucirumab and Docetaxel in Patients with Metastatic Urothelial Carcinoma Harboring Fibroblast Growth Factor Receptor Alterations: A Case Series and Literature Review. Journal of immunotherapy and precision oncology	KER Smith, EE Hitron, GA Russler, DA Baumgarten, MA Bilen	02/01/2020
Current Landscape of Immunotherapy in Genitourinary Malignancies. Advances in experimental medicine and biology	O Alhalabi, H Rafei, MA Bilen, AY Shah	01/01/2020
Immunotherapy in sarcomatoid renal cell carcinoma: A case for optimism. Cancer treatment and research communications	JT Brown, MA Bilen	01/01/2020
Nonbacterial Thrombotic Endocarditis and Widespread Skin Necrosis in Newly Diagnosed Lung Adenocarcinoma. Case reports in oncology	K Zakka, P Zakka, A Davarpanah, N Koshkelashvili, MA Bilen, T Owonikoko, B El-Rayes, M Akce	01/01/2020
Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report. Frontiers in oncology	MA Bilen, JF Jiang, CS Jansen, JT Brown, LR Harik, A Sekhar, H Kissick, SK Maithel, O Kucuk, B Carthon, VA Master	01/01/2020
Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. Frontiers in oncology	P Barata, W Hatton, A Desai, V Koshkin, E Jaeger, C Manogue, P Cotogno, M Light, B Lewis, J Layton, O Sartor, A Basu, D Kilari, H Emamekhoo, MA Bilen	01/01/2020
Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. Investigational new drugs	DJ Martini, Y Liu, JM Shabto, C Lewis, MR Kline, H Collins, M Akce, HT Kissick, BC Carthon, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, VA Master, BF El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey, MA Bilen	12/01/2019
An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature	CS Jansen, N Prokhnevska, VA Master, MG Sanda, JW Carlisle, MA Bilen, M Cardenas, S Wilkinson, R Lake, AG Sowalsky, RM Valanparambil, WH Hudson, D McGuire, K Melnick, AI Khan, K Kim, YM Chang, A Kim, CP Filson, M Alemozaffar, AO Osunkoya, P Mullane, C Ellis, R Akondy, SJ Im, AO Kamphorst, A Reyes, Y Liu, H Kissick	12/01/2019
A Review of Papillary Renal Cell Carcinoma and MET Inhibitors. Kidney cancer (Clifton, Va.)	KE Rhoades Smith, MA Bilen	11/01/2019
Hybrid negative enrichment of circulating tumor cells from whole blood in a 3D-printed monolithic device. Lab on a chip	CH Chu, R Liu, T Ozkaya-Ahmadov, M Boya, BE Swain, JM Owens, E Burentugs, MA Bilen, JF McDonald, AF Sarioglu	10/09/2019
Management of metastatic renal cell carcinoma: The complexity of choice. EBioMedicine	JT Brown, MA Bilen	09/01/2019
Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. BMC cancer	MA Bilen, JM Shabto, DJ Martini, Y Liu, C Lewis, H Collins, M Akce, H Kissick, BC Carthon, WL Shaib, OB Alese, CE Steuer, C Wu, DH Lawson, R Kudchadkar, VA Master, B El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey	08/29/2019
MRI quantitation of abdominal skeletal muscle correlates with CT-based analysis: implications for sarcopenia measurement. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme	AI Khan, DA Reiter, A Sekhar, P Sharma, NM Safdar, DH Patil, SP Psutka, WC Small, MA Bilen, K Ogan, VA Master	08/01/2019
Reply to Tumor-associated macrophages: "Good cop-bad cop". Cancer	MA Bilen, HT Kissick, RD Harvey	06/01/2019
Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. Cancer	G Sonpavde, N Agarwal, GR Pond, RJ Nagy, RH Nussenzveig, AW Hahn, O Sartor, TS Gourdin, L Nandagopal, EM Ledet, G Naik, AJ Armstrong, J Wang, MA Bilen, S Gupta, P Grivas, SK Pal, RB Lanman, A Talasaz, MB Lilly	05/01/2019
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. The Lancet. Oncology	N Martínez Chanzá, W Xie, M Asim Bilen, H Dzimitrowicz, J Burkart, DM Geynisman, A Balakrishnan, IA Bowman, R Jain, W Stadler, Y Zakharia, V Narayan, B Beuselinck, RR McKay, A Tripathi, R Pachynski, AW Hahn, J Hsu, SA Shah, ET Lam, TL Rose, AE Mega, N Vogelzang, MR Harrison, A Mortazavi, ER Plimack, U Vaishampayan, H Hammers, S George, N Haas, N Agarwal, SK Pal, S Srinivas, BA Carneiro, DYC Heng, D Bosse, TK Choueiri, LC Harshman	04/01/2019
Comparison of Outcomes in Patients With Muscle-invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder Preservation. American journal of clinical oncology	J Zhong, J Switchenko, NK Jegadeesh, RJ Cassidy, TW Gillespie, V Master, P Nieh, M Alemozaffar, O Kucuk, B Carthon, CP Filson, MA Bilen, AB Jani	01/01/2019
The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer	MA Bilen, DJ Martini, Y Liu, C Lewis, HH Collins, JM Shabto, M Akce, HT Kissick, BC Carthon, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, BF El-Rayes, VA Master, SS Ramalingam, TK Owonikoko, RD Harvey	01/01/2019
Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. European journal of cancer (Oxford, England : 1990)	MT Campbell, MA Bilen, AY Shah, E Lemke, E Jonasch, AM Venkatesan, E Altinmakas, C Duran, P Msaouel, NM Tannir	11/01/2018
The addition of chemotherapy in the definitive management of high risk prostate cancer. Urologic oncology	MJ Ferris, Y Liu, J Ao, J Zhong, M Abugideiri, TW Gillespie, BC Carthon, MA Bilen, O Kucuk, AB Jani	11/01/2018
Therapeutic Vaccines for Genitourinary Malignancies. Vaccines	GMA Dutcher, MA Bilen	08/12/2018
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Investigational new drugs	T Fujii, RR Colen, MA Bilen, KR Hess, J Hajjar, ME Suarez-Almazor, A Alshawa, DS Hong, A Tsimberidou, F Janku, J Gong, B Stephen, V Subbiah, SA Piha-Paul, S Fu, P Sharma, T Mendoza, A Patel, S Thirumurthi, A Sheshadri, F Meric-Bernstam, A Naing	08/01/2018
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Investigational new drugs	RR Colen, T Fujii, MA Bilen, A Kotrotsou, S Abrol, KR Hess, J Hajjar, ME Suarez-Almazor, A Alshawa, DS Hong, D Giniebra-Camejo, B Stephen, V Subbiah, A Sheshadri, T Mendoza, S Fu, P Sharma, F Meric-Bernstam, A Naing	08/01/2018
Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab. Clinical genitourinary cancer	MA Bilen, GMA Dutcher, Y Liu, D Ravindranathan, HT Kissick, BC Carthon, O Kucuk, WB Harris, VA Master	06/01/2018
Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer	N Agarwal, SK Pal, AW Hahn, RH Nussenzveig, GR Pond, SV Gupta, J Wang, MA Bilen, G Naik, P Ghatalia, CJ Hoimes, D Gopalakrishnan, PC Barata, A Drakaki, BM Faltas, LA Kiedrowski, RB Lanman, RJ Nagy, NJ Vogelzang, KM Boucher, UN Vaishampayan, G Sonpavde, P Grivas	05/15/2018
The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma. Expert opinion on investigational drugs	MA Bilen, JW Carlisle, G Sonpavde	02/01/2018
Metastatic Prostate Cancer Manifesting as Cholestatic Jaundice: A Case Report and Review of the Literature. Case reports in oncological medicine	D Ravindranathan, EE Hitron, GA Russler, Y Xue, MA Bilen	01/01/2018
Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma. Oncoimmunology	KS Kim, RR Sekar, D Patil, MA Dimarco, HT Kissick, MA Bilen, AO Osunkoya, VA Master	01/01/2018
A novel preoperative inflammatory marker prognostic score in patients with localized and metastatic renal cell carcinoma. Asian journal of urology	RR Sekar, D Patil, Y Baum, J Pearl, A Bausum, MA Bilen, O Kucuk, WB Harris, BC Carthon, M Alemozaffar, CP Filson, JG Pattaras, PT Nieh, K Ogan, VA Master	10/01/2017
Frailty and cancer: Implications for oncology surgery, medical oncology, and radiation oncology. CA: a cancer journal for clinicians	CG Ethun, MA Bilen, AB Jani, SK Maithel, K Ogan, VA Master	09/01/2017
Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer chemotherapy and pharmacology	MA Bilen, KR Hess, SK Subudhi, A Aparicio, J Kim, AJ Zurita-Saavedra, JC Araujo, PG Corn, J Stover, SH Lin, CJ Logothetis, SM Tu	09/01/2017
Proteomics Profiling of Exosomes from Primary Mouse Osteoblasts under Proliferation versus Mineralization Conditions and Characterization of Their Uptake into Prostate Cancer Cells. Journal of proteome research	MA Bilen, T Pan, YC Lee, SC Lin, G Yu, J Pan, D Hawke, BF Pan, J Vykoukal, K Gray, RL Satcher, GE Gallick, LY Yu-Lee, SH Lin	08/04/2017
Safety of Same-day Pegfilgrastim Administration in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel With or Without Carboplatin. Clinical genitourinary cancer	MA Bilen, DH Cauley, BJ Atkinson, HC Chen, DH Kaya, X Wang, R Vikram, SM Tu, PG Corn, J Kim	06/01/2017
Recent developments in the management of germ cell tumors. Current opinion in oncology	P Msaouel, MA Bilen, M Zhang, M Campbell, J Wang, SM Tu	05/01/2017
Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget	MA Bilen, KR Hess, MT Campbell, J Wang, RR Broaddus, JA Karam, JF Ward, CG Wood, SL Choi, P Rao, M Zhang, A Naing, R General, DH Cauley, SH Lin, CJ Logothetis, LL Pisters, SM Tu	12/27/2016
Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer	SM Tu, MA Bilen, KR Hess, RR Broaddus, S Kopetz, C Wei, LC Pagliaro, JA Karam, JF Ward, CG Wood, P Rao, ZH Tu, R General, AH Chen, YL Nieto, SC Yeung, SH Lin, CJ Logothetis, LL Pisters	06/15/2016
Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. Journal for immunotherapy of cancer	MA Bilen, SK Subudhi, J Gao, NM Tannir, SM Tu, P Sharma	01/01/2016

Awards

Mentorship of Graduate Students Award, Winship Cancer Institute, 2018
Top Clinical Trials Enroller - All Sites and Top Clinical Trials Enroller - NCTN Trials, Winship Cancer Institute, 2018
Emory Woodruff Health Sciences Synergy Award, 2018
Winship Invest$ Pilot Grant Award, 2018
Winship Invest$ Prostate Cancer Research Pilot Award, 2017
Top clinical trial enrollment (Clifton campus), Winship Cancer Institute, July-December 2017
Waun Ki Hong Award for Clinical Investigation, UT MD Anderson Cancer Center, 2016
ASCO/AACR Methods in Clinical Cancer Research Workshop, 2015

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.

4.9	One star One star One star One star One half star	Provider showed concern
4.9	One star One star One star One star One half star	Provider explained things clearly
4.9	One star One star One star One star One half star	Provider discussed treatment options
4.9	One star One star One star One star One half star	Provider included you in decisions
4.9	One star One star One star One star One half star	Likelihood of recommending this provider

View Reviews


One star One star One star One star One star	06/28/2025	Only dealt with Dr Bilen. He is prompt and extremely professional and takes the time with patients. I am fortunate to have him as my MO
One star One star One star One star One star	06/28/2025	Dr Bilen is wonderful!
One star One star One star One star One star	06/25/2025	Great Doctor
One star One star One star One star One star	06/22/2025	Dr. Bilen is an excellent communicator and very caring and personable. Very punctual too.
One star One star One star One star One star	06/21/2025	Dr Bilen is a great doctor Very knowledgeable and thorough in explaining what my options are for the treatment.
One star One star One star One star One star	05/30/2025	Dr. Bilen is excellent. His whole team is wonderful.
One star One star One star One star One star	05/17/2025	My interaction with Dr. Bilen has been very positive. His communication style is very reassuring.
One star One star One star One star One star	05/09/2025	We were so impressed by Dr Bilen. His knowledge, demeanor, empathy and kindness were all exemplary.
One star One star One star One star One star	04/26/2025	Dr Bilen is excellent!
One star One star One star One star One star	04/04/2025	Dr. Bilen's communication skills are outstanding! We are very pleased we have him in our corner.
One star One star One star One star One star	03/08/2025	Dr. Bilen is great.
One star One star One star One star One star	02/28/2025	Great experience with Dr Bilen sharing fantastic news.
One star One star One star One star One star	02/26/2025	Dr exceeded all expectation
One star One star One star One star One star	02/05/2025	Outstanding in every way!
One star One star One star One star One star	01/21/2025	Dr Bilen is excellent..I really appreciate him.
One star One star One star One star One star	01/19/2025	Great customer service
One star One star One star One star One star	01/15/2025	Dr. Bilen is exceptional!
One star One star One star One star One star	01/07/2025	Very concern and caring
One star One star One star One star One star	12/23/2024	Dr Bilen has been really great. He explains what's going on, my options and answers all of my questions
One star One star One star One star One star	12/18/2024	Dr. Bilen was excellent. We left feeling so much better about my treatment and the hope we have for a positive outcome.
One star One star One star One star One star	11/18/2024	Dr Bilen is one of the best oncologist I've had. Considerate, good ear, knowledgeable, compassionate. A special person.
One star One star One star One star One star	11/13/2024	The doctor did an excellent job of informing us of all the options, answering our questions, was friendly and professional, and we really appreciated his time and service.
One star One star One star One star One star	11/01/2024	Dr. Belin was very caring and compassionate as he went over my test results, and explained what was happening in my body. His answers to my questions regarding what to expect given my current course of treatment were clear and straightforward. I felt more confident about how to handle things going forward.
One star One star One star One star One star	10/24/2024	A fellow of Dr Belin was attending before dr Bilen came in and took questions and was very informative and caring.
One star One star One star One star One star	10/23/2024	Excellent
One star One star One star One star One star	10/18/2024	Good
One star One star One star One star One star	10/16/2024	Dr Bilan was outstanding He took gracious time with me and made me feel like a family member Outstanding patient care in his communication
One star One star One star One star One star	09/25/2024	Buena
One star One star One star One star One star	09/21/2024	The provider was very good and instructing me what I had to I would receiv
One star One star One star One star One star	09/18/2024	Excellent
One star One star One star One star One star	09/06/2024	Dr Bilen is unbelievably compassionate and supportive.
One star One star One star One star One star	08/29/2024	We met with Dr Bilen and he was great. He had reviewed my health history and was completely up to speed. He explained what he feels my health situation is and proposed a care plan that makes sense. It was our first visit with him and he was very good, very professional.
One star One star One star One star One star	08/23/2024	I feel very well cared for
One star One star One star One star One star	08/21/2024	Wish he was my everything doctor. Great bedside. Intelligent. Compassionate. Wow!
One star One star One star One star One star	08/16/2024	Very good
One star One star One star One star One star	08/12/2024	This is the first time ever that a virtual appointment was at the time scheduled. I am extremely impressed with Dr. Bilan.
One star One star One star One star One star	08/10/2024	Dr Bilen is one of the best physicians I have ever had. Compassionate, clear, concerned, knowledgeable.
One star One star One star One star One star	07/31/2024	Dr Bilen and complete staff are nothing short of Professional. I love my team!
One star One star One star One star One star	07/20/2024	This was the first time in a long time I felt there was hope for my future
One star One star One star One star One star	07/10/2024	Dr. Bilen treated me very professionally and was very clear with his explanations
One star One star One star One star One star	06/28/2024	Excellent experience
One star One star One star One star One star	06/21/2024	Dr Bilen is always available to patients for questions and/or concerns.
One star One star One star One star One star	06/21/2024	Dr Bilen is the best
One star One star One star One star One star	06/21/2024	For the last time..everything and everyone was great as always.
One star One star One star One star One star	06/21/2024	Dr. Bilan was excellent!
One star One star One star One star One star	05/25/2024	Dr Bilen is a such a great professional, very knowledgeable, very courteous, very considerate and concerned to make sure that I understood the situation and the next steps
One star One star One star One star One star	05/20/2024	Dr. Bilen has counseled me and my wife through a diagnosis of incurable cancer, treatment options, and finally when to cease treatment. These have been some of the most difficult decisions I have ever had to make. Dr. Bilen has shown compassion, empathy, and concern, but equally as importantly he has never shied away from tough discussions. He is a gem. I have been blessed to know him.
One star One star One star One star One star	05/06/2024	Good dialog with Dr on issues , concerns, next steps, opportunities. Proactive in discussion tumor board and potential for proton therapy
One star One star One star One star One star	04/14/2024	I had some very difficult treatment decisions to make. Dr. Bilen was empathetic. He listened. He offered caring advice. I am fortunate to have him by my side.
One star One star One star One star One star	04/09/2024	Dr. Bilen is wonderful and always includes our wishes in Brian's care plan!
One star One star One star One star One star	03/30/2024	Dr. Bilen is one of the best!
One star One star One star One star One star	03/27/2024	Dr. Bilen has always been excellent.
One star One star One star One star One star	03/23/2024	Dr Bilen had nothing but great news about lab and CT scans plus setting up our next appointment in August at Johns Creek Hospital.
One star One star One star One star One star	03/05/2024	The care providers has gone beyond their professional care. I have never encountered a group of medical professionals who have shown their most concern for my care. If I could I would rate them as number one, Thank you all.
One star One star One star One star One star	02/18/2024	Excellent!
One star One star One star One star One star	02/18/2024	The doctor and his team are wonderful
One star One star One star One star One star	01/24/2024	Dr. Bilen is an excellent physician.
One star One star One star One star One star	01/21/2024	Dr. Bilen took his time to make my conditions and my options clear.
One star One star One star One star One star	01/19/2024	Dr. Billen is a wonderful physician.
One star One star One star One star One star	01/10/2024	Dr. Bilen is the best. Great attitude and great listener.
One star One star One star One star One star	12/26/2023	Dr. Bilen always seems to care about how I feel. He takes a lot of time with me and explains my situation so I can understand. I respect his professionalism.
One star One star One star One star One star	12/20/2023	Dr. Bilen is the most caring physician I've ever had. There is no doubt that he's in the perfect profession. His empathy is unmatched by most physicians and health care workers. And, he's kind to his staff, nurses, and everyone.
One star One star One star One star One star	12/15/2023	Dr. Bilen always takes time to listen and explain things very carefully. He is extremely empathetic and never makes me feel like he is rushed, although I know he is very busy.
One star One star One star One star One star	12/15/2023	Dr Bilen is one of my reasons I come to Emory for my oncology needs. He is so knowledgeable and compassionate.
One star One star One star Empty star Empty star	12/09/2023	Video visit was rushed. Limited opportunity for questions.
One star One star One star One star One star	12/08/2023	Dr. Bilen is the best!
One star One star One star One star One star	12/04/2023	Dr Bilen is alway patient and shows concern.
One star One star One star One star One star	11/22/2023	Dr Bilen is a fantastic person. He took his time and explained my treatment options in great depth. His exceptional knowledge was of great benefit to me.
One star One star One star One star One star	11/16/2023	Good
One star One star One star One star One star	11/10/2023	Dr. Bilen and his staff are outstanding knowledgeable and professional
One star One star One star One star One star	11/07/2023	Good
One star One star One star One star One star	11/03/2023	Dr. Bilen is excellent physician
One star One star One star Empty star Empty star	10/25/2023	I understand the providers have limited time with each patient, but it feels frustrating when the provider doesn't listen to all patient concerns (including side effects) and quickly moves on to the next topic.
One star One star One star One star One star	10/15/2023	Dr Bilen listened to my concerns and made a plan with my input
One star One star One star One star One star	09/29/2023	He is fantastic!
One star One star One star One star One star	09/17/2023	Excellent experience
One star One star One star One star One star	09/09/2023	100% of the time was with Dr Bilen. So appreciative
One star One star One star One star One star	09/06/2023	Dr. Bilen, his nursing staff, and Sierra Williams his research coordinator for oncology clinical programs are the best. They make you feel like they are taking the best care of you....like you are truly their family member.
One star One star One star One star One star	09/05/2023	True gentleman
One star One star One star One star One star	08/22/2023	Very through explanations.
One star One star One star One star One star	08/06/2023	Dr. Bilen is wonderful
One star One star One star One star One star	08/04/2023	Dr. Bilen is the best oncologist I've had. He helped me getting me in contact with the clinic's dietitian and getting a Bayer grant to get Darolutamide free. Gives me all the time I need and does not leave until all my questions and concerns have been answered. Very attentive and very concerned. The patient as a whole comes first for him: addressing the sickness is crucial, but caring for the patient, the person, comes first. The Way all physicians should be.
One star One star One star One star One star	07/31/2023	Marva is marvelous! She has never missed an IV and I'm a tough stick:) She is amazing!!!